TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed or refractory SAA or very SAA defined:~  * Bone marrow (\< 25% cellular)~ * Peripheral cytopenias (at least 2 of 3)~    * ANC \< 500 per ml~   * Platelets \< 20,000 per ml~   * Absolute retic \< 60,000 or corrected retic \< 1%~ * Very severe: as above, but ANC \< 200~ * Disease may be designated as acquired or inherited if previous counts known (these other bone marrow failure disorders that are characterized by aplastic anemia may go by additional names such as dyskeratosis congenita or PNH)~ * Failed at least one course of immunosuppressive therapy (if presumed acquired disease). Patients with inherited disease will be characterized as refractory and do not require immunosuppressive first.~* Age 0- upper age limit as determined by current institutional standards~* Good performance status (ECOG 0 or 1; Karnofsky and Lansky 70-100)~* Patients and donors must be able to sign consent forms (or if a minor the parent will sign). Donors should be willing to donate.~* Patients must be geographically accessible and willing to participate in all stages of treatment.~* Adequate end-organ function as measured by:~  1. Left ventricular ejection fraction \> or = to 35%, or shortening fraction \> 25% (For pediatric patients, a normal ejection fraction is required)~ 2. Bilirubin ≤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST ≤ 5 x ULN~ 3. FEV1 and FVC \> or = to 40% of predicted; or in pediatric patients, if unable to perform pulmonary function tests due to young age, oxygen saturation \>92% on room air~Exclusion Criteria:~* Patients will not be excluded on the basis of sex, racial or ethnic background.~* Prior transfusions from selected donor (as this could have cause recipient alloimmunization against the donor)~* Women of childbearing potential who currently are pregnant (HCG+) or who are not practicing adequate contraception.~* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up.~* Uncontrolled viral, bacterial, or fungal infections (HIV infection permitted if viral load undetectable)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 73 Years
- Healthy Volunteers: f

Study Arms:
- Bone marrow transplant (Type: EXPERIMENTAL): Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Two Hand Hygiene Products in ICUs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HCW willing to participate in the study~* HCW willing to use non-Triclosan soap when soap is necessary throughout the study~* HCW who will don gloves prior to ICU patient room entry~Exclusion Criteria:~* Use of any CHG -containing products ( liquid hand soap, Sage wipes) on the ICU 72 hours prior to study initiation and throughout study~* HCW with patient bandage or other dressing on palm(s)~* Known sensitivity or allergy to CHG or alcohols in hand hygiene products~* Known sensitivity or allergy to the following components: Lecithin, Polysorbate 80,Trypticase Soy Agar, sodium bisulfate, sodium thioglycollate, sodium thiosulfate~* History of skin allergies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Alcohol hand sanitizer foam (Type: ACTIVE_COMPARATOR): Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
- hand antiseptic with CHG and alcohol (Type: ACTIVE_COMPARATOR): Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, who is at least 18 years of age or older.~* A clinical diagnosis of rosacea.~* A Clinician Erythema Assessment (CEA) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1.~* A Patient Self Assessment-5 (PSA-5) score of 3 at Screening and at Pre-dose (T0) on Baseline/Day 1.~* A Patient Self Assessment-11 (PSA-11) score of 5 at Screening and at Pre-dose (T0) on Baseline/Day 1.~Exclusion Criteria:~* Three (3) or more facial inflammatory lesions.~* Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.~* Known allergies or sensitivities to any components of the study medications, including the active gel ingredient, brimonidine tartrate.~* Intraocular pressure (IOP) measurement less than 10 mm Hg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD07805/47 Gel 0.5% QD (Type: EXPERIMENTAL): None
- CD07805/47 Gel 0.18% QD (Type: EXPERIMENTAL): None
- CD07805/47 Gel 0.18% BID (Type: EXPERIMENTAL): None
- Vehicle Gel QD (Type: PLACEBO_COMPARATOR): None
- Vehicle Gel BID (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. LDL-C between 100 and 190 mg/dL~2. Hepatic fat under 6.2% per MRS~Exclusion Criteria:~1. Pregnant or lactating females~2. Uncontrolled hypertension \>180/95 mmHg~3. Chronic renal insufficiency - serum creatinine \>2.5 mg/dL at screen~4. Liver disease; i.e., hepatitis, cirrhosis~5. Major surgery within 3 months of screen~6. Cardiac insufficiency~7. Hx of malignancy other than basal or squamous cell within past 5 yrs~8. Participation in any investigational drug study within 6 wks of screen~9. Prior exposure to AEGR-733 in past 12 months~10. Serious or unstable medical or psychological conditions~11. More than one alcoholic drink per day~12. Regular consumption of grapefruit juice or meds known to be metabolized by CYP 3A4~13. Currently taking corticosteroids~14. Other lipid-lowering meds (washout permitted)~15. Fish oil, niacin grater than 200 mg/day and herbal weight loss products (washout permitted)~16. Acute CVD or event within previous 6 months~17. Diabetes Mellitus~18. Hepatitis B or C~19. Medicated COPD~20. Idiopathic pulmonary fibrosis~21. G.I. disorders that cause chronic diarrhea~22. Fasting triglycerides =/\> 400 mg/dL~23. Body Mass Index \> 35kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): 2.5 mg AEGR-733
- 3 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733
- 4 (Type: ACTIVE_COMPARATOR): 7.5 mg AEGR-733
- 5 (Type: ACTIVE_COMPARATOR): 10 mg AEGR-733
- 6 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733 + 20 mg atorvastatin
- 7 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733 + 145 mg fenofibrate
- 8 (Type: ACTIVE_COMPARATOR): 5 mg AEGR-733 + 10 mg ezetimibe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2835219 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy sterile males or surgically sterile or postmenopausal females~* Have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m\^2), inclusive, at screening~* Are able to eat a high-fat, high-calorie meal~Exclusion Criteria:~* Participated in a clinical trial involving investigational product within 30 days~* Abnormal blood pressure~* Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study~* Have donated blood of more than 500 milliliter (mL) within the last month~* Show evidence of human immunodeficiency virus, hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY2835219 Standard (Type: EXPERIMENTAL): Single oral dose of LY2835219 given with a standard meal in one of three study periods.
- LY2835219 Fasted (Type: EXPERIMENTAL): Single oral dose of LY2835219 given with no food in one of three periods.
- LY2835219 High-Fat (Type: EXPERIMENTAL): Single oral dose of LY2835219 given with a high fat meal in one of three periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hematological neoplasms or solid tumors candidable to high-dose chemotherapy with autologous peripheral stem cell reinfusion~* Adequate organ function~* Written informed consent.~Exclusion Criteria:~* Use of other experimental drugs~* Active infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Filgrastim (Type: ACTIVE_COMPARATOR): Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
- Pegfilgrastim (Type: EXPERIMENTAL): Pegfilgrastim administered the day after autologous stem-cell reinfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Treatment for Alcoholics With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the criteria for alcohol dependence with comorbid bipolar disorder.~* Agreement to participate in outpatient treatment.~* Ability to tolerate lithium carbonate and be randomized to receive sodium valproate or placebo.~* Stable living situation.~* Ability to provide informed consent.~Exclusion Criteria:~* Psychiatric conditions including schizophrenia, schizoaffective disorder, any non-bipolar psychotic disorder, unipolar major depression, mental retardation, or signs of impaired cognitive functioning.~* Neurological conditions including epilepsy, history of brain injury, encephalitis, or any organic brain syndrome or focally abnormal electroencephalographic examination.~* Medical conditions including severe cardiac, liver, kidney, endocrine, hematologic, other impairing or unstable medical condition or impending surgery.~* Persistent elevation of liver function enzymes indicating active liver disease.~* Pregnancy or not using an acceptable contraceptive method.~* Inability to read or understand study forms; agree to informed consent.~* Impending incarceration or a mandate to attend treatment by the legal system for an alcohol use disorder.~* The presence of either/or cocaine dependence, opioid dependence, and intravenous drug use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- sodium valproate (Type: ACTIVE_COMPARATOR): sodium valproate was added on treatment as usual and dose monitored by blood level measurements
- placebo (Type: PLACEBO_COMPARATOR): Placebo comparator was added on treatment as usual and dose monitored by blood level measurements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Smoking Reduction Intervention for Smoking Parents of Paediatric Patients in Hong Kong

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ethnic Chinese family with children aged younger than 18 years of age.~* Children who are admitted to the paediatric inpatient units or attend the paediatric specialist clinic at the Prince of Wales Hospital.~* Children with at least one custodial smoking parent who is living with them.~* Written informed consent obtained from parents.~Exclusion Criteria:~* Families not residing in Hong Kong.~* Children in foster care.~* Children with unclear custody.~* Smoking paediatric patients.~* Presence of smoking household members apart from the parents.~* Smoking parent who is contraindicated to use nicotine replacement therapy.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Intervention arm will include face-to-face counseling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of free NRT, referral to quit smoking hotline, monthly phone follow-up and two follow-up visits.
- Control (Type: NO_INTERVENTION): Smoking parents will be given standard advice on smoking cessation. They will be given an information leaflet showing standard information on the currently available smoking cessation service as well as a smoking cessation hotline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* premature neonates \< 33 weeks gestational age~Exclusion Criteria:~* major congenital anomalies~* prior use of cytokines

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: f

Study Arms:
- G-CSF (Type: EXPERIMENTAL): None
- EPO (Type: EXPERIMENTAL): None
- G-CSF and EPO (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ramipril - Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* no previous antihypertensive therapy~* high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg)~Exclusion Criteria:~* antihypertensive therapy~* blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Condition in Giant Obese Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* multimorbid, super-super obese patients~Exclusion Criteria:~* renal insufficiency III

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Super-super Obese Patients (Type: OTHER): Multimorbid, super-super obese patients that need preoperative conditioning therapy (intervention 1: Liraglutide, intervention 2: aminosteril hepa 8%, intervention 3: Caloric diet with 1000 kcal) for weight loss surgery to achieve technical operability.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tai Chi for Chronic Low Back Pain in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • Be men or women at least 65 years of age~  * Have low back pain that has persisted for at least three months~ * Have had back pain on at least half the days in the last 6 months~ * Have at least moderate intensity low back pain~ * Have some activity limitations due to back pain~ * Be members of Kaiser Permanente Washington integrative health care system or have a regular source of health care and health insurance~ * Have normal cognition or only mild cognitive impairment~ * Be capable of understanding the study procedures and complying with them for the entire study period.~ * Live close enough to the class site for attendance to be practical~ * Give informed consent~Exclusion Criteria:~* • Have certain specific conditions of LBP~  * Prior lumbar spine surgery~ * Have sciatica, or scheduled visits to a neurosurgeon or orthopedic surgeon.~ * Receiving or seeking compensation for back pain~ * Red flags of serious underlying illness~ * Have practiced Tai Chi or yoga recently. Have other disabling conditions that might confound treatment effects~ * Conditions making consent or treatment difficult~ * Conditions making treatment unsafe or inappropriate~ * Unwillingness to give informed consent

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tai Chi (Type: EXPERIMENTAL): twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
- Health Education (Type: ACTIVE_COMPARATOR): twice weekly classes for 12 weeks
- Usual Medical Care (Type: ACTIVE_COMPARATOR): the usual care to which participants are entitled by their health insurance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Females aged 40-62 years~* Postmenopausal or perimenopausal~* Having bothersome hot flashes~* In general good health~* Signed informed consent~Exclusion Criteria:~* Recent use of systemic hormone therapy or hormonal contraceptives~* Recent use of any prescribed, over-the-counter or herbal therapies that are taken specifically for hot flashes~* Recent use of selective estrogen receptor modulators (SERMS) or aromatase inhibitors~* Recent use of psychotropic medications, including SSRIs (selective serotonin reuptake inhibitors), serotonin-norepinephrine reuptake inhibitors (SNRIs), MAOIs (monoamine oxidase inhibitors), and other antidepressants and anxiolytics.~* Known hypersensitivity or contraindications (reasons not to take) to venlafaxine, estrogen, or progestins~* Not using a medically approved method of birth control, if sexually active and not 12 or more months since last menstrual period~* Recent drug or alcohol abuse~* Lifetime diagnosis of psychosis or bipolar disorder~* Suicide attempt in the past 3 years or any current suicidal ideation~* Current major depression (assessed during screening)~* Pregnancy, intending pregnancy, or breast feeding~* History of:~  * Pre-breast cancer or high-risk breast cancer condition~ * Abnormal bleeding suggestive of endometrial pre-cancer or endometrial hyperplasia~ * Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable or under medical management~* Abnormal screening blood tests~* Current participation in another drug trial or intervention study~* Inability or unwillingness to complete the study procedures

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 62 Years
- Healthy Volunteers: t

Study Arms:
- Low-dose 17-ß-estradiol with progesterone taper (Type: ACTIVE_COMPARATOR): None
- Venlafaxine XR (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete